NASDAQ:KZIA

Kazia Therapeutics News Headlines

$9.88
-0.42 (-4.08 %)
(As of 06/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.81
$10.26
50-Day Range
$9.10
$12.13
52-Week Range
$3.12
$15.85
Volume73,928 shs
Average Volume123,311 shs
Market Capitalization$128.06 million
P/E RatioN/A
Dividend YieldN/A
Beta2.71

Kazia Therapeutics (NASDAQ KZIA) News Headlines Today

SourceHeadline
Short Interest in Kazia Therapeutics Limited (NASDAQ:KZIA) Decreases By 14.3%Short Interest in Kazia Therapeutics Limited (NASDAQ:KZIA) Decreases By 14.3%
americanbankingnews.com - June 18 at 5:40 PM
Here’s why the Kazia Therapeutics (ASX:KZA) share price got a 6% boost todayHere’s why the Kazia Therapeutics (ASX:KZA) share price got a 6% boost today
msn.com - June 16 at 8:57 PM
How Many Kazia Therapeutics Limited (ASX:KZA) Shares Did Insiders Buy, In The Last Year?How Many Kazia Therapeutics Limited (ASX:KZA) Shares Did Insiders Buy, In The Last Year?
finance.yahoo.com - June 16 at 8:57 PM
Kazia Therapeutics to collaborate with Cornell University for new paxalisib phase II clinical trialKazia Therapeutics to collaborate with Cornell University for new paxalisib phase II clinical trial
proactiveinvestors.com - June 16 at 10:57 AM
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for GlioblastomaKazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
finance.yahoo.com - June 15 at 12:47 PM
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First PatientStudy of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
finance.yahoo.com - June 7 at 8:34 AM
Up 220% in 1-year, Kazia Therapeutics (ASX:KZA) share price is edging lower todayUp 220% in 1-year, Kazia Therapeutics (ASX:KZA) share price is edging lower today
msn.com - June 6 at 10:10 PM
Kazia Therapeutics to Present at LD Micro Invitational XIKazia Therapeutics to Present at LD Micro Invitational XI
finance.yahoo.com - June 3 at 11:26 AM
Kazia Therapeutics directors demonstrate confidence in bio-tech strategy with on-market purchasesKazia Therapeutics directors demonstrate confidence in bio-tech strategy with on-market purchases
proactiveinvestors.com.au - June 2 at 7:37 AM
Kazia Therapeutics directors demonstrate confidence in company with on-market purchasesKazia Therapeutics directors demonstrate confidence in company with on-market purchases
proactiveinvestors.com.au - May 4 at 2:01 PM
Kazia Therapeutics (ASX:KZA) Is In A Good Position To Deliver On Growth PlansKazia Therapeutics (ASX:KZA) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - May 3 at 9:24 AM
The eggs files: why hens are at the centre of modern scienceThe eggs files: why hens are at the centre of modern science
finance.yahoo.com - May 1 at 9:08 AM
Edison Investment Research Limited: Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesisEdison Investment Research Limited: Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis
finanznachrichten.de - April 20 at 3:05 PM
Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesisKazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis
finance.yahoo.com - April 20 at 3:05 PM
Kazia Therapeutics licenses global rights to novel, first-in class, clinic-ready oncology drug candidate EVT801Kazia Therapeutics licenses global rights to novel, first-in class, clinic-ready oncology drug candidate EVT801
proactiveinvestors.com - April 19 at 11:30 PM
Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
finanznachrichten.de - April 19 at 8:28 AM
Kazia Therapeutics licensing deals result in A+ rating and $2.60 price target from Corporate ConnectKazia Therapeutics licensing deals result in A+ rating and $2.60 price target from Corporate Connect
proactiveinvestors.com - April 14 at 5:31 AM
Edison Investment Research Limited: Kazia Therapeutics (KZIA): Paxalisib Chinese Rights LicensedEdison Investment Research Limited: Kazia Therapeutics (KZIA): Paxalisib Chinese Rights Licensed
finanznachrichten.de - March 31 at 1:46 PM
Kazia Therapeutics (KZIA): Paxalisib Chinese Rights LicensedKazia Therapeutics (KZIA): Paxalisib Chinese Rights Licensed
finance.yahoo.com - March 30 at 12:43 PM
Why the Kazia Therapeutics (ASX:KZA) share price is rocketing 11%Why the Kazia Therapeutics (ASX:KZA) share price is rocketing 11%
msn.com - March 30 at 12:30 AM
Kazia Therapeutics enters one of world’s largest pharma markets through Chinese licensing deal for paxalisib with Simcere PharmaceuticalKazia Therapeutics enters one of world’s largest pharma markets through Chinese licensing deal for paxalisib with Simcere Pharmaceutical
proactiveinvestors.com - March 29 at 7:15 PM
Kazia Therapeutics Stock Is Trading Higher On Paxalisib Licensing Agreement In Greater ChinaKazia Therapeutics Stock Is Trading Higher On Paxalisib Licensing Agreement In Greater China
finance.yahoo.com - March 29 at 1:37 PM
Kazia Therapeutics CEO and MD highlights 2021 progress with focus on providing treatment for diagnosed glioblastomaKazia Therapeutics CEO and MD highlights 2021 progress with focus on providing treatment for diagnosed glioblastoma
proactiveinvestors.com.au - March 18 at 6:51 AM
Kazia Therapeutics grants Oasmia exclusive rights for first-in-class ovarian cancer drug candidate CantrixilKazia Therapeutics grants Oasmia exclusive rights for first-in-class ovarian cancer drug candidate Cantrixil
proactiveinvestors.com.au - March 2 at 11:07 PM
How Is Kazia Therapeutics (ASX:KZA) CEO Paid Relative To Peers?How Is Kazia Therapeutics' (ASX:KZA) CEO Paid Relative To Peers?
finance.yahoo.com - February 1 at 12:06 AM
Kazia Therapeutics has a unique PI3K inhibitor for brain tumors: H.C. Wainwright & Co.Kazia Therapeutics has a unique PI3K inhibitor for brain tumors: H.C. Wainwright & Co.
proactiveinvestors.com.au - January 19 at 3:57 PM
KZIA Mar 2021 10.000 callKZIA Mar 2021 10.000 call
au.finance.yahoo.com - December 24 at 12:44 AM
KZIA Jun 2021 10.000 callKZIA Jun 2021 10.000 call
au.finance.yahoo.com - December 22 at 11:12 PM
CEO, MD & Executive Director James Garner Just Bought 10% More Shares In Kazia Therapeutics Limited (ASX:KZA)CEO, MD & Executive Director James Garner Just Bought 10% More Shares In Kazia Therapeutics Limited (ASX:KZA)
finance.yahoo.com - December 17 at 6:06 PM
Kazia Therapeutics to collaborate with Pacific Pediatric Neuro-Oncology Consortium for new paxalisib combination study in DIPGKazia Therapeutics to collaborate with Pacific Pediatric Neuro-Oncology Consortium for new paxalisib combination study in DIPG
proactiveinvestors.com.au - December 9 at 10:37 PM
Edison Investment Research Limited: Kazia Therapeutics (KZIA): Phase IIa Shows Good Safety, Consistent EfficacyEdison Investment Research Limited: Kazia Therapeutics (KZIA): Phase IIa Shows Good Safety, Consistent Efficacy
finanznachrichten.de - December 4 at 9:51 PM
Should You Take Comfort From Insider Transactions At Kazia Therapeutics Limited (ASX:KZA)?Should You Take Comfort From Insider Transactions At Kazia Therapeutics Limited (ASX:KZA)?
finance.yahoo.com - November 26 at 9:54 PM
APVO Gets Buyout Offer, PFE/BNTX COVID Shot 95% Effective, CORT Gets Favorable PTAB RulingAPVO Gets Buyout Offer, PFE/BNTX' COVID Shot 95% Effective, CORT Gets Favorable PTAB Ruling
nasdaq.com - November 19 at 3:14 AM
Why Kazia Therapeutics Stock Is Trading Higher TodayWhy Kazia Therapeutics Stock Is Trading Higher Today
benzinga.com - November 18 at 5:12 PM
Kazia stock +22% on positive paxalisib data in glioblastomaKazia stock +22% on positive paxalisib data in glioblastoma
seekingalpha.com - November 18 at 7:11 AM
Kazia Therapeutics to present paxalisib data confirming earlier safety and efficacy results in glioblastoma at SNOKazia Therapeutics to present paxalisib data confirming earlier safety and efficacy results in glioblastoma at SNO
proactiveinvestors.com.au - November 17 at 11:06 PM
Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In GlioblastomaKazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma
finance.yahoo.com - November 17 at 6:06 PM
Kazia Therapeutics completes $25.2 million capital raisingKazia Therapeutics completes $25.2 million capital raising
proactiveinvestors.com.au - October 22 at 11:15 PM
Kazia Therapeutics executes agreement to begin GBM Agile pivotal studyKazia Therapeutics executes agreement to begin GBM Agile pivotal study
proactiveinvestors.com - October 18 at 12:36 AM
Kazia Therapeutics directors support company through entitlement offer participationKazia Therapeutics directors support company through entitlement offer participation
proactiveinvestors.com.au - October 14 at 9:32 AM
Kazia Therapeutics completes $16.4 million institutional entitlement offer to fund Paxalisib registration trialKazia Therapeutics completes $16.4 million institutional entitlement offer to fund Paxalisib registration trial
proactiveinvestors.com.au - October 3 at 10:42 PM
Kazia Therapeutics halted with news pending on accelerated entitlement offerKazia Therapeutics halted with news pending on accelerated entitlement offer
proactiveinvestors.com - October 1 at 10:33 PM
Kazia inks clinical pact with Dana-farber Cancer Institute for its lead asset in primary CNS lymphomaKazia inks clinical pact with Dana-farber Cancer Institute for its lead asset in primary CNS lymphoma
seekingalpha.com - September 22 at 12:05 PM
Kazia Therapeutics to collaborate with Dana-Farber Cancer Institute in paxalisib clinical trial for primary CNS lymphomaKazia Therapeutics to collaborate with Dana-Farber Cancer Institute in paxalisib clinical trial for primary CNS lymphoma
proactiveinvestors.com.hk - September 22 at 2:02 AM
Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS LymphomaKazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma
markets.businessinsider.com - September 22 at 2:02 AM
US FDA Starting to Grant Fast-Track Designation for Glioblastoma TreatmentsUS FDA Starting to Grant Fast-Track Designation for Glioblastoma Treatments
marketwatch.com - September 16 at 9:54 AM
Kazia Therapeutics bringing a vetted drug class to the brain: EdisonKazia Therapeutics bringing a vetted drug class to the brain: Edison
proactiveinvestors.com.hk - September 9 at 5:06 AM
We're Hopeful That Kazia Therapeutics (ASX:KZA) Will Use Its Cash WiselyWe're Hopeful That Kazia Therapeutics (ASX:KZA) Will Use Its Cash Wisely
finance.yahoo.com - September 1 at 3:28 AM
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPGUS FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG
finance.yahoo.com - August 31 at 1:30 AM
Kazia Wins Orphan Drug Designation for anti-Cancer DrugKazia Wins Orphan Drug Designation for anti-Cancer Drug
baystreet.ca - August 24 at 12:44 PM
This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.